Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each dropping 1.1%.
The iShares Biotechnology ETF (IBB) slipped 0.8%.
In corporate news, Eli Lilly's (LLY) weight loss drug Mounjaro will be rolled out initially to people with the highest clinical need in England over the next three years, according to the National Institute for Health and Care Excellence's draft guidance. Eli Lilly shares shed 0.5%.
Eli Lilly, Pfizer (PFE) and Pharmaceutical Research and Manufacturers of America executives dined with US President-elect Donald Trump on Wednesday night and held various discussions including potential public-private collaborations to find cures for cancer, Axios reported. Pfizer shares popped 2.2%.
Protara Therapeutics (TARA) shares surged past 75%. The company said its investigational therapy TARA-002 showed a complete response rate of 72% at six months in a phase 2 trial involving people with non-muscle invasive bladder cancer.
Novo Nordisk (NVO) said Thursday it plans to significantly reduce the list price paid by US customers for its Tresiba and Fiasp insulin products starting January 2026. Its shares were 0.1% higher.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。